Axinn Successfully Obtains Dismissal of Certain Patent Claims asserted against Zydus Pharmaceuticals in Boehringer Ingelheim Pharmaceuticals, Inc. v. HEC Pharma Co., Ltd.
December 19, 2016
A team of Axinn attorneys successfully obtained a dismissal of certain patent claims brought by Boehringer Ingelheim Pharmaceuticals against several defendants, including Axinn client Zydus Pharmaceuticals. On December 7, the United States District Court for the District of New Jersey granted the Defendants’ joint motion to dismiss the claims of patent infringement relating to U.S. Patent No. 8,853,156, which is alleged by Boehringer to cover its antidiabetic drug Tradjenta (linagliptin).
At issue in the matter was whether claims that recite a method of treating metabolic diseases by administering DPP-IV inhibitors to certain patients are patent eligible under 35 U.S.C. § 101. The Defendants challenged the asserted certain of the ‘156 patent on grounds that they recite a natural law and are therefore patent ineligible. The plaintiffs argued that the claims were patent eligible because they recite treating specific populations using non-natural compounds and alter the state of the body in a new and useful way.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Hanging in the Balance: Supreme Court Declines to Decide the Uninjured Class Member Question in Labcorp v. Davis
Axinn Viewpoints
Antitrust
New Incentives, New Rewards: What You Need to Know About the Antitrust Division’s First-Ever Whistleblower Rewards Program
Axinn Viewpoints
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
How I Made Partner: 'Show Up and Build Rapport With Colleagues and Clients,' Says Michael O'Mara of Axinn Veltrop & Harkrider
Media Mentions
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property